Core Viewpoint - A class action lawsuit has been filed against Navan, Inc. for allegedly misleading investors regarding its IPO and subsequent financial performance, leading to significant losses for shareholders [2][7]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of all individuals and entities who purchased Navan securities based on the Offering Documents [2]. - Investors have until April 24, 2026, to apply to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that the Offering Documents used during Navan's IPO were false and misleading, failing to disclose an increase in "sales and marketing" expenses at the time of the offering [7]. - As a result of the revelations about the company's business practices, Navan's share price fell dramatically, trading as low as $9.01 per share, which is over a 60% decline from the IPO price of $25.00 per share [7]. Group 3: Company Background - Navan conducted its initial public offering on October 30, 2025, selling approximately 36.9 million shares [7]. - Bragar Eagel & Squire, P.C. is a law firm representing investors in this case, with a focus on securities and commercial litigation [5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Corcept (CORT) To Contact Him Directly To Discuss Their Options If you purchased or acquired Corcept common stock between October 31, 2024, and December 30, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- What’s Happeni ...

Core Viewpoint - A class action lawsuit has been filed against Ostin Technology Group Co., Ltd. for alleged securities fraud during the class period from May 11, 2025, to June 26, 2025, with significant losses reported by investors [2][5]. Allegation Details - The lawsuit alleges that on September 12, 2025, a criminal indictment was unsealed against Ostin's co-CEO Lai Kui Sen and financial advisor Yan Zhao, charging them with conspiracy to commit securities fraud and wire fraud, resulting in over $110 million in illicit proceeds [5]. - The complaint claims that starting in April 2025, Lai Kui Sen and co-conspirators executed fraudulent securities offerings, allowing them to acquire Ostin shares at minimal or no cost, while simultaneously inflating the stock price through deceptive promotional campaigns [5]. - Ostin's market capitalization reportedly increased from approximately $22 million to over $1 billion during the class period, with the stock price peaking at $9.40 on June 26, 2025, before a significant selloff led to a loss of over $950 million in market capitalization in one day [5]. Next Steps - Investors who purchased Ostin shares and suffered losses are encouraged to contact Bragar Eagel & Squire, P.C. for more information regarding their rights and potential claims [4].

Core Insights - Supernus Pharmaceuticals, Inc. is actively participating in multiple investor conferences in March 2026, showcasing its commitment to engaging with investors and stakeholders in the biopharmaceutical sector [1][2][3]. Conference Participation - The company will attend the TD Cowen 46th Annual Health Care Conference on March 2, 2026, with a fireside chat scheduled for 2:30 p.m. ET in Boston, Massachusetts [1]. - Supernus will also participate in the Jefferies Biotech on the Beach Summit on March 10, 2026, held in Miami Beach, Florida [2]. - Additionally, the company is set to present at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, with a fireside chat at 2:00 p.m. ET in Miami Beach, Florida [3]. Webcast Availability - Live audio webcasts of the TD Cowen and Barclays Conference presentations will be accessible on the Supernus Pharmaceuticals website, with archived replays available for 60 days post-conference [4]. Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases, indicating a specialized niche within the biopharmaceutical industry [5]. - The company's neuroscience portfolio includes approved treatments for various conditions such as ADHD, Parkinson's disease-related dyskinesia, postpartum depression, epilepsy, and migraine, among others [6].

Core Viewpoint - The FDA has placed a partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab, affecting new patient enrollment due to recent safety events [1][2]. Group 1: FDA Clinical Hold - The partial clinical hold was initiated after MacroGenics notified the FDA of a temporary pause in enrollment due to safety events involving four patients, including Grade 4 thrombocytopenia (2 patients), Grade 4 myocarditis (1 patient), and Grade 4 neutropenia with concurrent septic shock leading to a Grade 5 event (1 patient) [2]. - No new patients will be enrolled in the LINNET study until the hold is lifted, but current participants can continue receiving the study drug [1][2]. Group 2: LINNET Study Details - The LINNET study evaluates lorigerlimab, a bispecific DART® molecule targeting PD-1 and CTLA-4, as monotherapy in patients with platinum-resistant ovarian cancer (PROC) and clear cell gynecologic cancer (CCGC) [3]. - The study is designed as a Simon two-stage trial, initially enrolling approximately 20 patients, with the potential to expand to an additional 20 patients if a predefined activity threshold is met [3]. - The primary endpoint of the study is the objective response rate (ORR), with multiple secondary endpoints [3]. Group 3: Company Overview - MacroGenics is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for cancer treatment [4]. - The company generates its pipeline from proprietary next-generation antibody-based technology platforms, enabling strategic collaborations with global pharmaceutical and biotechnology companies [4].

Record 4Q and Full Year Performance at Work Truck Solutions; Record Parts & Accessories Sales at Work Truck Attachments Full Year 2025 Highlights* Consolidated Net Sales increased 15.4% to $656.1 millionWinter weather drove robust Parts & Accessories sales across the company, particularly in 4QDelivered Diluted Earnings per Share (EPS) of $1.96; Adjusted Diluted EPS increased 52.0% to $2.24Both segments produced Net Sales and Adjusted EBITDA growth for both 4Q and Full Year 2025 Acquired Venco Venturo in 4Q ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- If you sold your Masonite International Corporation (“Masonite” or the “Company”) (NYSE:DOOR) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until April 7, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Gemini Space Station, Inc. (“Gemini” or the “Company”) (NASDAQ:GEMI) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On September 12, 2025, Gemini conducted its initial public offering, selling 15,937,501 shares of ...

TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX, OTCQB:BSXGF) is pleased to report that all meeting matters put forth to the shareholders (the “Shareholders”), as voted on by the disinterested shareholders, were duly approved at its special meeting of shareholders held today (the “Meeting”). At the Meeting, the 91.99% of the disinterested Shareholders approved the issuance of up to 56,565,697 common shares of the Company to La Mancha Investments S. à r ...

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Varonis Systems, Inc. (NASDAQ: VRNS) between February 4, 2025 and October 28, 2025, both dates inclusive (the “Class Period”), of the important March 9, 2026 lead plaintiff deadline. SO WHAT: If you purchased Varonis common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...